You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
2026 › March › 25
Merck
4 months ago
Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Merck nears $6bn biotech deal to boost cancer drug pipeline ⊖
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
page 1 of 1